Two previous studies have demonstrated that DISH patients have lower levels of adiponectin [30, 31], an adipokine that is associated with an increased risk in a dose response relationship for incident T2DM [32]. This evidence concerns the gene ADIPOQ and diffuse idiopathic skeletal hyperostosis.